<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244242</url>
  </required_header>
  <id_info>
    <org_study_id>527.16</org_study_id>
    <nct_id>NCT02244242</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Symptomatic Relief Effects of FLOMAX速 in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX速 Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate the symptomatic relief afforded by tamsulosin hydrochloride capsules in
      patients with signs and symptoms of benign prostatic hyperplasia (BPH). Additionally to
      provide primary care physicians experience with the use of tamsulosin hydrochloride capsules
      0.4 mg daily for the treatment of BPH
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <primary_completion_date type="Actual">August 1999</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in American Urological Association (AUA) Symptom Score Index by means of a patient self-assessment questionnaire</measure>
    <time_frame>up to 45 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of AUA Bother Score Index by means of a patient self-assessment questionnaire</measure>
    <time_frame>up to 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BPH Impact Index by means of a patient self-assessment questionnaire</measure>
    <time_frame>up to 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of investigator on 5-point scale</measure>
    <time_frame>at 4, 8 and 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 59 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">493</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified release capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin hydrochloride</intervention_name>
    <arm_group_label>Tamsulosin hydrochloride</arm_group_label>
    <other_name>Flomax速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients (45 years of age or older) diagnosed with BPH who scores at least 13
             points on the AUA Symptom Score Index at baseline

          -  Patients who have a baseline Prostate specific antigen (PSA) of &gt;= 4.0 ng/ml

          -  Patients who provide written informed consent prior to participation in the study in
             accordance with regulatory requirements

          -  Patients who have been judged by the investigator to be reliable and who have agreed
             to cooperate with all tests and examinations stipulated in the protocol

        Exclusion Criteria:

          -  Patients who have previously been diagnosed with prostate cancer

          -  Patients who have an abnormal Digital rectal examination (DRE) of the prostate gland
             at baseline other than enlargement (i.e., patients with suspicious areas or nodularity
             of the gland which may indicate possible prostatic carcinoma are to be excluded)

          -  Patients who have had previous invasive or non-invasive surgical treatment of the
             prostate gland

          -  Patients who have had an episode of acute urinary retention within four weeks of the
             screening visit

          -  Patients who have a history or evidence of urethral stricture

          -  Patients who have had pelvic radiotherapy

          -  Patients who have a history of chronic prostatitis

          -  Patients who have a history of neurogenic bladder

          -  Patients who have had a urinary tract infection (i.e. positive urine culture yielding
             pathogenic bacteria &gt;= 10**5 colony forming units per ml or a laboratory report of a
             urinary tract infection) or symptoms/signs indicative of a urinary tract infection
             such as: increased white blood cells (WBCs) in the urine (15-30 WBC/high powered field
             [hpf], dysuria, costovertebral tenderness and urinary frequency accompanied by fever
             within four weeks of baseline

          -  Patients who have evidence of significant renal dysfunction based upon a serum
             creatinine greater than two times the upper limit of normal levels established by the
             central laboratory used in this study

          -  Patients who have baseline clinical laboratory test results that indicate the
             following values:

               -  Hemoglobin: &lt; 12.0 g/dl

               -  Leukocytes: &lt; 3000 mm続

               -  Liver enzymes: Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic
                  Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) and alkaline
                  phosphatase): More than two times the upper limit of normal levels established by
                  the central laboratory used in the study

          -  Patients who have postural symptoms (e.g. lightheadedness, dizziness and fainting
             occurring with or without a change in Blood Pressure (BP) and/or Heart Rate (HR)
             within four weeks of baseline

          -  Patients who have participated in another drug study within four weeks of baseline

          -  Patients who have clinically relevant conditions which might interfere with the
             patient's ability to participate in the study including (but not limited to) the
             following:

               -  neurologic, gastrointestinal, cardiovascular (including uncontrolled hypertension
                  defined as a sitting diastolic BP &gt;= 95 mmHg with or without treatment), hepatic,
                  renal, psychiatric, hematologic or respiratory disease or clinically relevant
                  laboratory abnormalities based upon the investigator's judgment

          -  Patients who have had cancer or a diagnosis of cancer within five years of baseline

          -  Patients who have received cimetidine, warfarin or herbal medication specifically for
             treatment of any urological problems within four weeks prior or baseline

          -  Patients who have known allergy to study medication

          -  Patients who are currently receiving finasteride or who have been treated with
             finasteride within three months prior to baseline

          -  Patients who have documented myocardial infarction (by ECG) within the past 6 months
             or evidence of a myocardial infarction on an ECG where the date could not be
             determined

          -  Patients who are classified as New York Heart Association (NYHA) Class III or IV
             congestive heart failure

          -  Patients who have prosthetic heart valves, cardiac devices or history of endocarditis

          -  Patient who have clinically significant cardiac arrhythmias as diagnosed by ECG
             whether or not accompanied by symptoms (e.g., dizziness, presyncope, syncope,
             unsteadiness)

          -  Patients who have received the following drugs within two weeks prior to baseline and
             who are unable to discontinue these drugs for the remainder of the study:

               1. Alpha-adrenergic blocking agents

               2. Alpha-adrenergic agonists

               3. Drugs with anticholinergic activity including antihistamines

               4. Antispasmodics

               5. Parasympathomimetics and cholinomimetics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

